Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial.
More information about the protocols and merits of the study, as well as the research that has led to the FDA's oversight of a patient trial, is available on the San Diego Academy of Regenerative Therapies (SDARTS.com) Online Learning Platform.
The Panel discussion recorded on October 1, 2020, features Dr. Alexander and Dr. Ramon Llull, MD, Ph.D., a research colleague who has done extensive studies on the use of cellular Stromal Vascular Fraction.
Tulip Medical is a subsidiary of SDARTs.
Patients considering participation in this clinical trial should email Dr. Alexander at irbtrials@gmail.com.
Watch the Panel Discussion Webinar with Dr. Alexander and Dr. Ramon Llull.
Read Dr. Alexander's newest article detailing the diagnostic and treatment protocol for this ground-breaking clinical trial in Stem Cell Research.
Read Dr. Llull's latest article characterizing adipose tissue's regenerative capabilities in the Journal of Plastic and Reconstructive Surgery.
Tulip Medical develops and markets medical devices and systems for using adipose tissue for plastic surgery, dermatology, regenerative medicine, and anti-aging patient applications.
Tulip holds numerous patents on medical devices and methods designed to help medical practitioners harness and deliver the benefits of fat to millions of patients.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT